- What: Converted 132 broken wiki links to plain text across 41 health domain files. Added Vida to the Active Agents table in CLAUDE.md. - Why: Leo's PR #15 review required these two changes before merge. - Details: Broken links were references to claims that don't yet exist (demand signals). Brackets removed so they read as plain text rather than broken links. Co-Authored-By: Claude Opus 4.6 <noreply@anthropic.com>
38 lines
5.9 KiB
Markdown
38 lines
5.9 KiB
Markdown
---
|
|
description: Preventive health platform co-started by Zachary Werner and Mark Hyman offering 100-plus lab tests and AI-powered MRI for 499 per year with 350M total raised at 2.5B valuation using Costco model of break-even testing with membership margin
|
|
type: claim
|
|
domain: health
|
|
created: 2026-02-21
|
|
source: "Zachary Werner profile research, Devoted Health Series G deck references, a16z Series A announcement June 2024, Redpoint Series B announcement November 2025"
|
|
confidence: likely
|
|
---
|
|
|
|
# Function Health drives down diagnostic conversion costs to 499 per year for 100-plus lab tests making atoms-to-bits health data generation accessible at consumer scale
|
|
|
|
Function Health offers 100+ lab tests and AI-powered 22-minute MRI scans for $499/year. This is the Amazon playbook applied to diagnostics: relentlessly drive down the cost of the atoms-to-bits conversion until it becomes accessible to everyone, then own the customer relationship and the data that flows from it.
|
|
|
|
The same panel of tests through traditional insurance-based channels would cost $5,000-$10,000+. Function collapses this by 90%+, removing the insurance intermediary and going direct-to-consumer. The conversion point (biological sample → structured health data) is the same, but the access economics are fundamentally different.
|
|
|
|
**Team and investors.** Co-started by Zachary Werner (operational health-tech investor, VZVC co-founder), Mark Hyman, MD (former Cleveland Clinic functional medicine chief), and Jonathan Swerdlin (CEO, Werner's Wisdom VC co-founder). Raised $53M Series A led by Andreessen Horowitz in June 2024 at $191M valuation, then $298M Series B led by Redpoint Ventures in November 2025 at $2.5B valuation. $350M total raised. Celebrity investors include Matt Damon, Kevin Hart, Zac Efron, Pedro Pascal. The company has processed 50M+ lab tests and expanded to 130+ MRI locations through a Medical Intelligence Lab AI initiative.
|
|
|
|
**The atoms-to-bits thesis.** Werner believes that controlling the chokepoints where atoms transform into bits and owning the customer experience are essential. Software is getting easier, so the moat isn't in the AI interpretation layer. The moat is at the physical conversion point: the lab test, the MRI scan, the blood draw. Function Health's strategy is to drive down the cost of that conversion so aggressively that it becomes a consumer product rather than a medical event.
|
|
|
|
**The Costco model for diagnostics.** Function breaks even on testing and makes all its margin on membership fees. Werner has focused relentlessly on driving testing costs down. This creates structurally superior incentives compared to incumbents and standalone hardware companies. Quest and Labcorp profit from per-test markup, so they're incentivized to protect pricing. Oura profits from a ~$410 margin on a $420 ring, so they're incentivized to protect hardware premium. Function profits from member retention, so they're incentivized to make testing as cheap and accessible as possible and deliver outcomes that keep members coming back. The company that's structurally incentivized to drive conversion costs down will always win long-term because its priorities align with the consumer. This is Werner's "financial outcomes aligned with health outcomes" thesis expressed at the business model level.
|
|
|
|
Since [[healthcares defensible layer is where atoms become bits because physical-to-digital conversion generates the data that powers AI care while building patient trust that software alone cannot create]], Function Health is the purest expression of the atoms-to-bits strategy at the diagnostics conversion point. Every test generates data. The data feeds AI models that improve interpretation. Better interpretation attracts more members. More members fund further cost reduction. Flywheel.
|
|
|
|
**Competitive positioning.** Function Health's moat is at the lab/imaging infrastructure layer (atoms) combined with the consumer trust and longitudinal data (bits). Pure software health apps can't replicate the physical testing infrastructure. Traditional lab companies (Quest, Labcorp) have the infrastructure but not the consumer relationship or AI interpretation layer. Function occupies the intersection.
|
|
|
|
The platform has significant expansion potential. Since [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]], Function could integrate continuous wearable data between periodic lab tests, creating a complete picture: high-resolution periodic snapshots (labs) + continuous low-resolution monitoring (wearables). This would make standalone wearable companies increasingly vulnerable to bundling.
|
|
|
|
---
|
|
|
|
Relevant Notes:
|
|
- [[healthcares defensible layer is where atoms become bits because physical-to-digital conversion generates the data that powers AI care while building patient trust that software alone cannot create]] -- Function Health is the purest expression of atoms-to-bits strategy at the diagnostics conversion point
|
|
- Devoted Health proves that optimizing for member health outcomes is more profitable than extracting from them -- Function's outcomes-aligned model parallels Devoted's approach at the diagnostics conversion point
|
|
- [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]] -- Function could integrate continuous wearable data between periodic lab tests
|
|
- [[value in industry transitions accrues to bottleneck positions in the emerging architecture not to pioneers or to the largest incumbents]] -- diagnostics is a bottleneck position in healthcare's emerging architecture
|
|
- [[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]] -- Quest and Labcorp won't cannibalize their $100+ per test pricing to match Function's $5/test economics
|
|
|
|
Topics:
|
|
- health and wellness
|